labetalol has been researched along with Prostatic Hyperplasia in 1 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouffioux, CR | 1 |
| Penders, L | 1 |
1 review available for labetalol and Prostatic Hyperplasia
| Article | Year |
|---|---|
Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Labetalol; Male | 1984 |
1 trial available for labetalol and Prostatic Hyperplasia
| Article | Year |
|---|---|
Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Labetalol; Male | 1984 |